Jonathan Lim, Erasca CEO

Eras­ca touts ear­ly col­orec­tal can­cer da­ta, trims a slate of tri­als and pre­clin­i­cal pro­grams to re­fine fo­cus

Eras­ca be­lieves it’s se­cured the ear­ly clin­i­cal da­ta to show one of its tar­get­ed ther­a­pies holds promise as a “back­bone” for drug com­bi­na­tions, par­tic­u­lar­ly for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.